全文获取类型
收费全文 | 281767篇 |
免费 | 8960篇 |
国内免费 | 256篇 |
专业分类
耳鼻咽喉 | 2149篇 |
儿科学 | 10287篇 |
妇产科学 | 5538篇 |
基础医学 | 30331篇 |
口腔科学 | 3011篇 |
临床医学 | 26671篇 |
内科学 | 49971篇 |
皮肤病学 | 2185篇 |
神经病学 | 26020篇 |
特种医学 | 11946篇 |
外科学 | 42128篇 |
综合类 | 3657篇 |
一般理论 | 164篇 |
预防医学 | 30739篇 |
眼科学 | 4697篇 |
药学 | 16828篇 |
1篇 | |
中国医学 | 737篇 |
肿瘤学 | 23923篇 |
出版年
2023年 | 545篇 |
2022年 | 712篇 |
2021年 | 2144篇 |
2020年 | 1329篇 |
2019年 | 2115篇 |
2018年 | 24031篇 |
2017年 | 18985篇 |
2016年 | 21215篇 |
2015年 | 3301篇 |
2014年 | 4196篇 |
2013年 | 5863篇 |
2012年 | 14395篇 |
2011年 | 28642篇 |
2010年 | 22837篇 |
2009年 | 15286篇 |
2008年 | 26239篇 |
2007年 | 28915篇 |
2006年 | 7825篇 |
2005年 | 9445篇 |
2004年 | 10217篇 |
2003年 | 10775篇 |
2002年 | 8513篇 |
2001年 | 1591篇 |
2000年 | 1564篇 |
1999年 | 1439篇 |
1998年 | 1503篇 |
1997年 | 1312篇 |
1996年 | 1044篇 |
1995年 | 1086篇 |
1994年 | 943篇 |
1993年 | 791篇 |
1992年 | 818篇 |
1991年 | 771篇 |
1990年 | 808篇 |
1989年 | 736篇 |
1988年 | 665篇 |
1987年 | 577篇 |
1986年 | 567篇 |
1985年 | 617篇 |
1984年 | 574篇 |
1983年 | 489篇 |
1982年 | 492篇 |
1981年 | 437篇 |
1980年 | 405篇 |
1979年 | 338篇 |
1978年 | 354篇 |
1977年 | 240篇 |
1976年 | 248篇 |
1974年 | 297篇 |
1973年 | 232篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
12.
13.
14.
15.
N. S. Hari Narayana Moorthy Sergio F. Sousa Maria J. Ramos Pedro A. Fernandes 《Medicinal chemistry research》2016,25(7):1340-1357
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets. 相似文献
16.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
17.
18.
19.
20.
ABSTRACTCommunication between health professionals and patients is an intergroup phenomenon where the health professional has the most power and status. Over the past few decades, there has been a steady increase in the availability to patients of information about healthcare and specific diseases on the Internet. In this paper, we ask whether the use of Internet health information assists patients to manage their consultations with health professionals better and whether it alters the intergroup dynamic by providing a more equal status for patients. In this study 370 participants from Australia and Canada completed a survey that included a ‘willingness to communicate with health professionals’ scale. They also commented on their use and trust of Internet health information. Thematic analysis suggests that patients’ use of Internet health information serves as a broker between patients and their health provider in health consultations. We discuss the implications of these findings for health practitioners as they address how easier Internet access influences patient interactions with health professionals. We consider future research directions these finding provide in explaining communication behaviour in this context. 相似文献